In the world of drug development, the leap from concept to clinic is often a long and winding road. But Creative Biolabs is quietly reshaping that journey—one assay, one chip, one insight at a time.
Study of lead program will provide proof-of-concept to enable further clinical development in severe autoimmune diseases; full cohort data available in 2H'23 DNTH103 is a next-generation monoclonal ...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced publication of study results showing that inhibition of mannan-binding lectin-associated serine protease-2 (MASP-2) protects ...
Activation of the complement cascade of proteases has been linked to autoimmune and kidney diseases, including systemic lupus ...
Target Levels of Active Drug Achieved in Healthy Volunteers with Oral Twice-Daily Dosing; Supportive Impact on Pharmacodynamic Biomarker of Complement Activity ANX1502 Generally Well Tolerated Across ...
In a recent study published in Molecular Psychiatry, researchers review the anti-inflammatory effects of ketamine in the peripheral and central nervous systems. To this end, all relevant articles were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback